Treatment of elderly patients with chronic lymphocytic leukemia (Q37386705)

20 August 2017

1 reference

title

Treatment of elderly patients with chronic lymphocytic leukemia (English)

1 reference

20 August 2017

0 references

0 references

1 reference

1

Barbara Eichhorst

0 references

Valentin Goede

series ordinal

2

object named as

Valentin Goede

0 references

Michael Hallek

series ordinal

3

object named as

Michael Hallek

1 reference

20 August 2017

Valentin Goede

2

1 reference

20 August 2017

1 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

50

1 reference

20 August 2017

171-178

1 reference

20 August 2017

2

1 reference

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

20 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Prognostic importance of comorbidity in a hospital-based cancer registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Comorbidity and functional status are independent in older cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Quality of life in older people with cancer -- a gender perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

Effects of socio-demographic variables on health-related quality of life determined by the quality of life index--German version.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688517

10.1080/10428190802688517

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19197731